|  |  |
| --- | --- |
| **Agenda Item No:**  | **17b** |



|  |  |
| --- | --- |
| **Report to:**  | Humber & North Yorkshire Integrated Care Board |
| **Date of Meeting:** | 11 December 2024 |
| **Subject:** | **Question to the Board** |
| **Director Sponsor:** | Karina Ellis, Executive Director of Corporate Affairs |
| **Author:** | Mike Napier, Director of Governance and Board SecretaryGovernance & Compliance Team |

|  |
| --- |
| **STATUS OF THE REPORT:** Approve [ ]  Discuss [x]  Assurance [ ]  Information [ ]  A Regulatory Requirement [ ]  |

|  |
| --- |
| **SUMMARY OF REPORT:**In accordance with ICB procedures, public board meetings include a standing agenda item allowing members of the public to submit up to two questions in advance about any item on the published agenda. The ICB Chair has the discretion to decide whether to address questions not related to an agenda item during the meeting.A public question has been received and approved for consideration by the Chair as follows:*What progress, if any, has been made with the review of maternity provision across Humber and North Yorkshire? What process milestones and timescales have been adopted? In particular, rather than just undertaking statutory consultation on any significant proposed service changes arising from the review, is it the intention to initiate public engagement at the option development/appraisal stage?’*For Information Please refer to the link below for the publication of questions and answers previously submitted to the board. <https://humberandnorthyorkshire.icb.nhs.uk/public-questions-and-petitions/>**RECOMMENDATIONS:** Members are asked to:1. Receive the question and note that the response provided to the meeting will subsequently be sent in writing to the enquirer.
 |

|  |
| --- |
| **ICB STRATEGIC OBJECTIVE**  |

|  |
| --- |
| Leading for Excellence |[ ]
| Leading for Prevention |[ ]

|  |
| --- |
| Leading for Sustainability |[ ]
| Voice at the Heart |[x]

|  |
| --- |
| **IMPLICATIONS** |

|  |  |
| --- | --- |
| Finance | No adverse implications identified in relation to the submission of the question.  |
| Quality | No adverse implications identified in relation to the submission of the question.  |
| HR | No adverse implications identified in relation to the submission of the question.  |
| Legal / Regulatory | No adverse implications identified in relation to the submission of the question.  |
| Data Protection / IG | No adverse implications identified in relation to the submission of the question.  |
| Health inequality / equality | No adverse implications identified in relation to the submission of the question.  |
| Conflict of Interest Aspects | No adverse implications identified in relation to the submission of the question.  |
| Sustainability | No adverse implications identified in relation to the submission of the question.  |

|  |
| --- |
| **ASSESSED RISK:** There are no risks identified in relation to this paper.  |

|  |
| --- |
| **MONITORING AND ASSURANCE:** Monitoring and assurance of the matter will be undertaken by the ICB Board. |

|  |
| --- |
| **ENGAGEMENT:**In line with the ICB procedure, the Board Secretary will facilitate subsequent follow-up, as required. |

|  |
| --- |
| **REPORT EXEMPT FROM PUBLIC DISCLOSURE** No [x]  Yes [ ]  |